VivoSense develops and validates real-world digital clinical measures and provides end-to-end services and solutions for their delivery in regulated clinical trials.

VivoSense is dedicated to improving patient clinical research and care. Our hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. Delivering novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.

Our Mission


Advance Knowledge

We believe the study of human health in real-world, everyday environments is necessary to advance knowledge and discovery.


Body-Worn Monitoring

We make this possible by providing customized body-worn monitoring and analysis solutions rooted in scientific foundations.


Accurate Data Analysis

We enable the world’s best researchers to obtain the highest quality, real-world data and analyze it appropriately and accurately.

The VivoSense Story

“Measures that are trusted and valued by all stakeholders are the foundation on which all other innovation in digital health must be based." ~ Dudley Tabakin, chief executive officer of VivoSense

Since 2010, VivoSense has been helping clinical researchers analyze and interpret wearable sensor data to improve patient research and care. We are innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using our proprietary VivoSense® software.

The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. It allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.

Our mission is to realize the potential of novel measures and technologies in regulatory and medical decision-making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.

VivoSense closed a $25 Series A financing in March of 2022 to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). This financing will expand and refine our informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

Meet the Team

Board of Directors

Colin Bower

VivoSense CEO 

Dudley Tabakin

VivoSense Co-Founder & Chief Product Officer  

Chris Garabedian

CEO, Xontogeny and Portfolio Manager, PXV Fund 

Marc Cikes

Healthcare Investment Professional | Board Director | MD 

Lance Myers
Lance Myers, VivoSense Co-Founder

VivoSense Co-Founder

Core Values

Better Outcome for Patients

VivoSense is committed to the development of better medicines and medical interventions for improved patient outcomes.

Scientific Integrity

Guided by scientific principles, applying leading-edge methodologies with accuracy, academic transparency within the regulated framework required by our industry.


VivoSense never tells the customer anything but the scientific truth, never promising what cannot be delivered.

Diversity and Inclusion

VivoSense is committed to diversity and inclusion, where every voice is heard and the best-reasoned facts are those acted upon.

Environmental Responsibility

VivoSense strives for a minimal environmental impact, printing documents and traveling for business only when necessary.

Family Values

VivoSense recognizes the balance in work and family and provides for a flexible schedule, encouraging telecommuting whenever possible and minimizing the need for commuting at all times.